Cyclerion Therapeutics (NASDAQ:CYCN) Posts Earnings Results

Cyclerion Therapeutics (NASDAQ:CYCN) issued its quarterly earnings data on Tuesday. The company reported $0.22 earnings per share (EPS) for the quarter, Zacks reports. The business had revenue of $1.81 million for the quarter.

Cyclerion Therapeutics Trading Down 8.0 %

CYCN stock opened at $2.42 on Thursday. Cyclerion Therapeutics has a 52-week low of $1.27 and a 52-week high of $9.47. The business has a 50-day simple moving average of $3.15 and a two-hundred day simple moving average of $2.92.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc, a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc for the treatment of rare kidney disease.